Skip to main content
Caplight Logo









Couragene

Couragene

Private
New JerseyHealthcare & Life Scienceshttps://www.couragene.com/

Last Round

Grant

Sep 19, 2024

Total Funding Raised

$42.94M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Couragene is a biotechnology company that develops gene and biologic therapies using its proprietary Stimuli-responsive Traceless Engineering Platform (STEP) for the delivery of genetic medicines.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

non-viral deliverygene editinggenetic medicineCRISPR-Cas9in vivo deliverybiotechnologyneurogenetic disordersdrug deliverygene therapybiologic therapyoral drug deliverygenomic medicinebiotech startupdrug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Couragene Comparables

Compare Couragene with similar companies based on industry and business-model similarity.

Couragene comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Code Biotherapeutics
86%
Nanite, Inc.
85%
CyGenica
83%

Couragene Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantSep 19, 2024
GrantOct 10, 2023
SeedSep 6, 2022

Key People

Founding team and executive leadership

Xi Qin

Chief Financial Officer

Executive Team

Couragene Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 21, 2026

    Monthly visitors grew 1047% MoM, reaching 1.6K.

  • Apr 5, 2026

    Monthly visitors increased 46% MoM.

Couragene Filings

Explore SEC and related filing metadata, where available.

Couragene filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Couragene's valuation, stock price, and market status.

Is Couragene a public or private company?

Couragene is a private company.

What is the current stock price of Couragene?

Couragene is a private company with no public stock price. No recent secondary market data is available.

How much is Couragene worth (valuation)?

Valuation information for Couragene is not publicly available.

Can I buy Couragene stock?

Couragene shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Couragene's last funding round?

Couragene's most recent funding round was Grant on September 19, 2024.

Who are the main investors in Couragene?

Key investors in Couragene include Hi2 Global, Foothill Ventures, National Institute of Neurological Disorders and Stroke.

Will Couragene IPO soon?

No public IPO plans have been announced for Couragene.

How can I track Couragene secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Couragene's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNew Jersey
Employee Range4
Year Founded2022
Last FundingSep 19, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?